What are you looking for?
Faricimab and aflibercept 2 mg produced comparable short-term visual and anatomical outcomes in patients with diabetic macular oedema (DMO), according to a study. The study included 300 patients, with 292 eyes analyzed (191 aflibercept, 101 faricimab). Eyes were treatment-naïve or off therapy for ≥6 months and received a loading phase, with outcomes assessed at four... ...
The U.S. Food and Drug Administration has approved extended dosing intervals for EYLEA HD (aflibercept), allowing treatment up to every 20 weeks...
In another live recording of The Spotlight Series Podcast from the Hawaiian Eye Meeting, host Mario Nacinovich and Judy Kim, MD, of...
A US single-center retrospective study found that socioeconomic status was associated with differences in visual outcomes among patients treated for diabetic macular...
Significantly improvements in visual acuity and retinal anatomical structure over the course of 2 years were seen in patients with diabetic macular edema (DME) following a treat and extend regimen...